5,722 Shares in Solventum Co. (NYSE:SOLV) Bought by Marshall Wace LLP

Marshall Wace LLP purchased a new position in Solventum Co. (NYSE:SOLV - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 5,722 shares of the company's stock, valued at approximately $378,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Solventum by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company's stock valued at $1,074,591,000 after acquiring an additional 75,631 shares during the period. Geode Capital Management LLC grew its position in Solventum by 3.4% in the fourth quarter. Geode Capital Management LLC now owns 3,460,405 shares of the company's stock worth $227,992,000 after acquiring an additional 112,686 shares during the period. Norges Bank acquired a new stake in shares of Solventum during the 4th quarter worth about $203,740,000. Invesco Ltd. increased its position in shares of Solventum by 6.4% during the fourth quarter. Invesco Ltd. now owns 2,923,119 shares of the company's stock valued at $193,101,000 after acquiring an additional 176,201 shares during the last quarter. Finally, Boston Partners purchased a new stake in Solventum in the fourth quarter valued at approximately $110,378,000.

Solventum Stock Performance

Shares of SOLV traded down $1.28 during mid-day trading on Tuesday, reaching $65.61. 1,144,918 shares of the company's stock were exchanged, compared to its average volume of 1,281,029. The business's fifty day simple moving average is $71.25 and its 200-day simple moving average is $71.42. The stock has a market capitalization of $11.35 billion and a PE ratio of 23.86. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Wall Street Analysts Forecast Growth

SOLV has been the topic of a number of research reports. Piper Sandler reduced their target price on shares of Solventum from $84.00 to $80.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Bank of America lifted their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 26th. Mizuho raised their price target on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. Wells Fargo & Company lifted their price target on Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. Finally, Morgan Stanley raised their target price on Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, Solventum currently has an average rating of "Hold" and a consensus target price of $79.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.